Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
In the citing paper
“In contrast to these negative regulators of insulin action, SIRT1 appears to be a positive regulator of insulin sensitivity (43,44).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [43]
In the citing paper
“Additionally, the non-naturally occurring sirtuin-activating compound, SRT1720, has enhanced insulin sensitivity and oxidative metabolism in animal models of obesity, in part, by improving mitochondrial oxidative capacity231.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [231]
In the citing paper
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218). These compounds also improve insulin sensitivity in obese rodents (218).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Self-citationTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Self-citationSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Self-citation
Research works printed but not linked: 1
- Banks A, et al. Overexpression of the Sirtuin SIRT1 increases insulin sensitivity in aging mice. Diabetes. 2007;56(S1):0234-OR. [Google Scholar]
Cited by
Plant Polyphenols as Dietary Antioxidants in Human Health and Disease
Pandey, K. B., & Rizvi, S. I. (2009) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.2.5.9498 · Cited by 3,942
“Many mechanisms have been proposed to explain the anti-diabetic action of this stilbene, modulation of SIRT1 is one of them which improves whole-body glucose homeostasis and insulin sensitivity in diabetic rats.(50,68) It is reported that in cultured LLC-PK1 cells, high glucose induced cytotoxicity and oxidative stres…”
BackgroundAMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Self-citationFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Self-citationSirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Steinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
Recent progress in the biology and physiology of sirtuins
Finkel, T., Deng, C.-X., & Mostoslavsky, R. (2009) · Nature · doi:10.1038/nature08197 · Cited by 1,484
Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,349
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Insulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191
Self-citationImpact of Dietary Polyphenols on Carbohydrate Metabolism
Hanhineva, K., Törrönen, R., Bondia-Pons, I., Pekkinen, J., Kolehmainen, M., Mykkänen, H., & Poutanen, K. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11041365 · Cited by 1,157
“Sirtuins are a family of histone/protein deacetylases, among which, SIRT1 has been suggested to play a role in regulating glucose homeostasis and may be involved in the insulin signalling cascade [99,100].”
BackgroundMicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Spermidine in health and disease
Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018) · Science · doi:10.1126/science.aan2788 · Cited by 1,154
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
SIRT1 and other sirtuins in metabolism
Chang, H.-C., & Guarente, L. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.001 · Cited by 1,133
“In addition, SIRT1 activators like resveratrol [44] and newer sirtuin activating compounds (STACs) [45], exert effects that are similar to those of CR as revealed by measures of whole animal physiology [46] or by transcriptional profiling [47].”
BackgroundAdipose tissue expandability, lipotoxicity and the Metabolic Syndrome — An allostatic perspective
Virtue, S., & Vidal-Puig, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.12.006 · Cited by 1,013
Purushotham, A., Schug, T. T., Xu, Q., Surapureddi, S., Guo, X., & Li, X. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.006 · Cited by 1,003
“For example, activation of SIRT1 by the polyphenol resveratrol and several synthetic pharmacologic activators has been shown to protect against high-fat induced obesity and metabolic derangements (Baur et al., 2006; Lagouge et al., 2006; Milne et al., 2007).”
BackgroundThe Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1α
Zhong, L., D'Urso, A., Toiber, D., Sebastian, C., Henry, R. E., Vadysirisack, D. D., Guimaraes, A., Marinelli, B., Wikstrom, J. D., Nir, T., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.041 · Cited by 1,001
“In this context, whereas SIRT1 activators have been shown to protect against metabolic diseases such as type II diabetes, as published (Baur et al., 2006; Lagouge et al., 2006; Milne et al., 2007), in the case of SIRT6, inhibition rather than activation might prove beneficial to lower blood glucose in metabolic diseas…”
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Self-citationSirt1 protects against high-fat diet-induced metabolic damage
Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M., & Tschöp, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802917105 · Cited by 818
“More recently, selective Sirt1 activators have been shown to have beneficial effects on mitochondrial and metabolic function in obese rodents and offer potential for treating age-related metabolic diseases such as type 2 diabetes (14).”
BackgroundInfluentialSRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1
Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088682 · Cited by 915
AMPK and SIRT1: a long-standing partnership?
Ruderman, N. B., Julia Xu, X., Nelson, L., Cacicedo, J. M., Saha, A. K., Lan, F., & Ido, Y. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00745.2009 · Cited by 903
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899
“Compounds such as SRT1720, which more specifically target SIRT1 and have the similar effect on T2DM at lower doses, might facilitate clinical development (102, 207).”
BackgroundThe sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.004 · Cited by 837
“This strategy identified compounds like resveratrol or SRT1720 (Howitz et al., 2003; Milne et al., 2007), whose ability to directly interact with and activate SIRT1 is, however, debated (Pacholec et al., 2010).”
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Bonkowski, M. S., & Sinclair, D. A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.93 · Cited by 834
Self-citationBrown Remodeling of White Adipose Tissue by SirT1-Dependent Deacetylation of Pparγ
Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, S. R., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.027 · Cited by 799
“Activation of the NAD-dependent deacetylase SirT1 by small molecules, calorie restriction or exercise promotes mitochondrial biogenesis and activities (Cantó et al., 2009; Milne et al., 2007), raising the possibility that SirT1 regulates BAT functions.”
Calabrese, V., Cornelius, C., Dinkova-Kostova, A. T., Calabrese, E. J., & Mattson, M. P. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.3074 · Cited by 796
“In one study, the shortening of lifespan by the high-fat diet was reversed (305).”
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778
Sivitz, W. I., & Yorek, M. A. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2531 · Cited by 742
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218).”
Mitochondrial Energetics and Therapeutics
Wallace, D. C., Fan, W., & Procaccio, V. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092314 · Cited by 730
“The success of this approach has already been reported for several age-related diseases, including type 2 diabetes (274).”
A research agenda for aging in China in the 21st century
Fang, E. F., Scheibye-Knudsen, M., Jahn, H. J., Li, J., Ling, L., Guo, H., Zhu, X., Preedy, V., Lu, H., Bohr, V. A., et al. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.08.003 · Cited by 721
Feige, J. N., Lagouge, M., Canto, C., Strehle, A., Houten, S. M., Milne, J. C., Lambert, P. D., Mataki, C., Elliott, P. J., & Auwerx, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.017 · Cited by 719
“A new generation of selective synthetic SIRT1 activators structurally unrelated to resveratrol and with improved potency, efficacy, and specificity have recently been developed (Milne et al., 2007).”
BackgroundInfluentialSelf-citationTherapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Sirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
Nogueiras, R., Habegger, K. M., Chaudhary, N., Finan, B., Banks, A. S., Dietrich, M. O., Horvath, T. L., Sinclair, D. A., Pfluger, P. T., & Tschöp, M. H. (2012) · Physiological Reviews · doi:10.1152/physrev.00022.2011 · Cited by 711
“These molecules, 1,000 times more potent than resveratrol but structurally distinct (220), were shown to act through the same enzymatic mechanism, i.”
BackgroundInfluentialSelf-citationRegulation of SIRT1 in cellular functions: Role of polyphenols
Chung, S., Yao, H., Caito, S., Hwang, J.-W., Arunachalam, G., & Rahman, I. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.05.003 · Cited by 650
SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in Mice
Banks, A. S., Kon, N., Knight, C., Matsumoto, M., Gutiérrez-Juárez, R., Rossetti, L., Gu, W., & Accili, D. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.08.014 · Cited by 637
“Sirtuin agonists increase metabolic efficiency in rodents through a mechanism bearing similarity with calorie restriction (Baur et al., 2006; Lagouge et al., 2006; Milne et al., 2007).”
COPD as a Disease of Accelerated Lung Aging
Ito, K., & Barnes, P. J. (2009) · Chest · doi:10.1378/chest.08-1419 · Cited by 629
Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila
Burnett, C., Valentini, S., Cabreiro, F., Goss, M., Somogyvári, M., Piper, M. D., Hoddinott, M., Sutphin, G. L., Leko, V., McElwee, J. J., et al. (2011) · Nature · doi:10.1038/nature10296 · Cited by 624
Evidence for a common mechanism of SIRT1 regulation by allosteric activators
Hubbard, B. P., Gomes, A. P., Dai, H., Li, J., Case, A. W., Considine, T., Riera, T. V., Lee, J. E., E, S. Y., Lamming, D. W., et al. (2013) · Science · doi:10.1126/science.1231097 · Cited by 561
Self-citationTranscriptional Control of Mitochondrial Biogenesis and Function
Hock, M. B., & Kralli, A. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163119 · Cited by 614
“F or p er so na l u se o nl y. ANRV369-PH71-09 ARI 5 January 2009 14:42 Sirtuin 1 (SIRT1): NAD+-dependent protein deacetylase homologous to the yeast silent information regulator (Sir2) and implicated in caloric restriction and aging pathways Histone deacetylase (HDAC): a family of enzymes that deacetylate histones an…”
BackgroundInfluentialSirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Herranz, D., Muñoz-Martin, M., Cañamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., & Serrano, M. (2010) · Nature Communications · doi:10.1038/ncomms1001 · Cited by 612
Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Tabit, C. E., Chung, W. B., Hamburg, N. M., & Vita, J. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9134-4 · Cited by 572
“activators of the histone deacetylase SIRT1, have been shown to improve insulin sensitivity [209].”
BackgroundAntioxidant effects of resveratrol in the cardiovascular system
Xia, N., Daiber, A., Förstermann, U., & Li, H. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13492 · Cited by 574
“, 2010), whereas higher concentrations are needed to activate SIRT1 (high μM) (Howitz et al., 2003; Milne et al., 2007).”
BackgroundInfluentialSmall molecule SIRT1 activators for the treatment of aging and age-related diseases
Hubbard, B. P., & Sinclair, D. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.004 · Cited by 569
“SRT1460, SRT1720, and SRT2183) were discovered in a fluorescence polarization assay using a carboxytetramethylrhodamine (TAMRA)-tagged substrate and verified using mass spectrometry [8, 38, 39].”
InfluentialSelf-citationTissue-specific regulation of SIRT1 by calorie restriction
Chen, D., Bruno, J., Easlon, E., Lin, S.-J., Cheng, H.-L., Alt, F. W., & Guarente, L. (2008) · Genes & Development · doi:10.1101/gad.1650608 · Cited by 567
“These findings are consistent with the recent demonstration that resveratrol and the newer classes of SIRT1 activators do not induce gluconeogenesis in dosed animals (Baur et al. 2006; Lagouge et al. 2006; Milne et al. 2007).”
BackgroundResultSilent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion
Hsu, C.-P., Zhai, P., Yamamoto, T., Maejima, Y., Matsushima, S., Hariharan, N., Shao, D., Takagi, H., Oka, S., & Sadoshima, J. (2010) · Circulation · doi:10.1161/circulationaha.110.958033 · Cited by 560
A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange
Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J., Meyers, D. J., Cole, P., III, J. Y., et al. (2008) · Nature · doi:10.1038/nature07349 · Cited by 484
Self-citationFlavonoids as natural phenolic compounds and their role in therapeutics: an overview
Mutha, R. E., Tatiya, A. U., & Surana, S. J. (2021) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00161-8 · Cited by 626
“Stilbene compounds like resveratrol improvise whole-body glucose homeostasis and sensitivity to insulin in diabetic rats [26].”
BackgroundMitochondrial dysfunction and insulin resistance: an update
Montgomery, M. K., & Turner, N. (2015) · Endocrine Connections · doi:10.1530/ec-14-0092 · Cited by 527
Guarente, L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100831 · Cited by 510
Energetics, epigenetics, mitochondrial genetics
Wallace, D. C., & Fan, W. (2010) · Mitochondrion · doi:10.1016/j.mito.2009.09.006 · Cited by 505
Redox regulation of SIRT1 in inflammation and cellular senescence
Hwang, J.-W., Yao, H., Caito, S., Sundar, I. K., & Rahman, I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.015 · Cited by 503
“16 μM and maximum activation of SIRT1 of 781%), which improved glucose homeostasis and insulin sensitivity in three different animal models of type 2 diabetes and obesity [9, 188].”
The multifaceted functions of sirtuins in cancer
Chalkiadaki, A., & Guarente, L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3985 · Cited by 496
Smith, R. A. J., Hartley, R. C., Cochemé, H. M., & Murphy, M. P. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.010 · Cited by 499
Disruption of the Ang II type 1 receptor promotes longevity in mice
Benigni, A., Corna, D., Zoja, C., Sonzogni, A., Latini, R., Salio, M., Conti, S., Rottoli, D., Longaretti, L., Cassis, P., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36703 · Cited by 490
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 487
Self-citationEpigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
Wu, Y.-L., Lin, Z.-J., Li, C.-C., Lin, X., Shan, S.-K., Guo, B., Zheng, M.-H., Li, F., Yuan, L.-Q., & Li, Z.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01333-7 · Cited by 476
Bioactivities of Phenolics by Focusing on Suppression of Chronic Diseases: A Review
Shahidi, F., & Yeo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061573 · Cited by 474
“Resveratrol represses cyclooxygenase 1 activity, leading to a reduction in the accumulation of platelets [73], and exhibits anti-diabetes potential by modulating SIRT1, which contributes to the homeostasis of blood sugar content in diabetic rats [74].”
BackgroundSirtuin activators and inhibitors: Promises, achievements, and challenges
Dai, H., Sinclair, D. A., Ellis, J. L., & Steegborn, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.004 · Cited by 463
“Mechanisms of Sirtuin activation—Enzymatic characterization of SIRT1 activation by resveratrol suggested a lowering of the Km for the acetylated peptide substrate (Howitz et al., 2003; Milne et al., 2007), consistent with the proposed active site closure upon activator binding.”
BackgroundSelf-citationCalorie restriction and sirtuins revisited
Guarente, L. (2013) · Genes & Development · doi:10.1101/gad.227439.113 · Cited by 464
“…(resveratrol and newer, synthetic STACs) were reported to activate the enzyme in vitro by lowering its Km for substrate (Howitz et al. 2003) and also elicit health benefits in mice, especially in animals exposed to the high-fat diet (Baur et al. 2006; Lagouge et al. 2006; Milne et al. 2007).”
BackgroundInsulin signaling meets mitochondria in metabolism
Cheng, Z., Tseng, Y., & White, M. F. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.005 · Cited by 449
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside
Winnik, S., Auwerx, J., Sinclair, D. A., & Matter, C. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv290 · Cited by 422
“chondrial activation, and subsequent prevention of obesity along with an improvement of the diabetic phenotype.(76,77) Moreover, STAC improved survival and healthspan in obese mice.”
BackgroundSelf-citationWhat Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H.-Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 437
“Ten studies have been identified which investigated the effect of Resv on blood glucose levels, using genetically obese mice or rats, dietary induced obesity or chemically induced diabetes by STZ or alloxan [21,73,83,85,94,97–101].”
Sirtuin signaling in cellular senescence and aging
Lee, S.-H., Lee, J.-H., Lee, H.-Y., & Min, K.-J. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.290 · Cited by 435
“Especially, SRT1720, a synthetic STACs structurally unrelated to resveratrol, has been reported to improve insulin sensitivity and mitochondrial capacity in obese rodents (118),”
BackgroundTargeting Sirtuin 1 to Improve Metabolism: All You Need Is NAD+?
Cantó, C., & Auwerx, J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003905 · Cited by 433
“A more recent screening for other possible small molecular SIRT1 activators provided a second batch of compounds, among which SRT1720 has been best characterized (Milne et al., 2007).”
BackgroundInfluentialRETRACTED: SIRT1 Suppresses β-Amyloid Production by Activating the α-Secretase Gene ADAM10
Donmez, G., Wang, D., Cohen, D. E., & Guarente, L. (2010) · Cell · doi:10.1016/j.cell.2010.06.020 · Cited by 432
“SIRT1 has been implicated in protection against metabolic syndrome and diabetes, and sirtuin activators may offer promising new treatments for these increasingly common disorders (Milne et al., 2007).”
RetractedRole of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation
Singh, V., & Ubaid, S. (2020) · Inflammation · doi:10.1007/s10753-020-01242-9 · Cited by 427
Resveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426
“We first assessed the deacetylation of Fluor de Lys-SIRT1 peptide substrate that has been widely used in the literature to assess SIRT1 deacetylase activity (6,12).”
BackgroundMethodSirtuins — novel therapeutic targets to treat age-associated diseases
Lavu, S., Boss, O., Elliott, P. J., & Lambert, P. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2665 · Cited by 426
Self-citationAMP-activated protein kinase and its downstream transcriptional pathways
Cantó, C., & Auwerx, J. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0454-z · Cited by 421
“Similar observations were made with the SIRT1 agonist described by Sirtris, SRT1720 [159, 160], even though the direct and specific effects of this compound on SIRT1 activation are controversial [161].”
ResultSIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity
Yoshizaki, T., Schenk, S., Imamura, T., Babendure, J. L., Sonoda, N., Bae, E. J., Oh, D. Y., Lu, M., Milne, J. C., Westphal, C., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00417.2009 · Cited by 419
Self-citationSIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes
Yoshizaki, T., Milne, J. C., Imamura, T., Schenk, S., Sonoda, N., Babendure, J. L., Lu, J.-C., Smith, J. J., Jirousek, M. R., & Olefsky, J. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00705-08 · Cited by 415
Self-citationResveratrol: Its Biologic Targets and Functional Activity
Pervaiz, S., & Holme, A. L. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2412 · Cited by 405
Caloric restriction, SIRT1 and longevity
Cantó, C., & Auwerx, J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.03.008 · Cited by 395
Nampt: linking NAD biology, metabolism and cancer
Garten, A., Petzold, S., Körner, A., Imai, S.-I., & Kiess, W. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.10.004 · Cited by 398
“Because sirtuins have recently emerged as promising pharmaceutical targets to develop therapeutic interventions against age-associated diseases[59,60], the systemic enhancement of NAD biosynthesis might provide another pharmacological means to activate Sirt1 and to convey benefits against age-associated diseases[61].”
The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet
Mitchell, S. J., Martin-Montalvo, A., Mercken, E. M., Palacios, H. H., Ward, T. M., Abulwerdi, G., Minor, R. K., Vlasuk, G. P., Ellis, J. L., Sinclair, D. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.01.031 · Cited by 398
“There is mounting evidence that overexpression of SIRT1 in mice and use of small molecule activators of SIRT1, such as resveratrol and SRT1720, enhance insulin sensitivity and protect against diet-induced impairments in mitochondrial capacity and oxidative metabolism in laboratory animals (Banks et al., 2008; Feige et…”
BackgroundSelf-citationMitochondrial dysfunction in the pathophysiology of renal diseases
Che, R., Yuan, Y., Huang, S., & Zhang, A. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00571.2013 · Cited by 394
Rivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.027 · Cited by 391
Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases
Imai, S.-I., & Guarente, L. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.003 · Cited by 390
Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization
van Loosdregt, J., Vercoulen, Y., Guichelaar, T., Gent, Y. Y. J., Beekman, J. M., van Beekum, O., Brenkman, A. B., Hijnen, D.-J., Mutis, T., Kalkhoven, E., et al. (2010) · Blood · doi:10.1182/blood-2009-02-207118 · Cited by 388
Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase
Guarani, V., Deflorian, G., Franco, C. A., Krüger, M., Phng, L.-K., Bentley, K., Toussaint, L., Dequiedt, F., Mostoslavsky, R., Schmidt, M. H. H., et al. (2011) · Nature · doi:10.1038/nature09917 · Cited by 383
Self-citationPharmacological approaches to restore mitochondrial function
Andreux, P. A., Houtkooper, R. H., & Auwerx, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4023 · Cited by 383
Are sirtuins viable targets for improving healthspan and lifespan?
Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G., & de Cabo, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3738 · Cited by 382
Sirtuin functions and modulation: from chemistry to the clinic
Carafa, V., Rotili, D., Forgione, M., Cuomo, F., Serretiello, E., Hailu, G. S., Jarho, E., Lahtela-Kakkonen, M., Mai, A., & Altucci, L. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0224-3 · Cited by 387
“Mice treated with resveratrol display improved mitochondrial functions and protection against high-fat diet-induced obesity [100], while in obese mice, treatment with resveratrol leads to increased healthspan and lifespan [101].”
BackgroundYang, H., Zhang, W., Pan, H., Feldser, H. G., Lainez, E., Miller, C., Leung, S., Zhong, Z., Zhao, H., Sweitzer, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046364 · Cited by 377
“In addition to endogenous regulation of SIRT1, direct pharmacological modulators of SIRT1 activity have also been reported [33].”
BackgroundSelf-citationSeven sirtuins for seven deadly diseases ofaging
Morris, B. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.525 · Cited by 377
“[47] was what prompted the extensive molecular screening, irrespective of structure, for SIRT1 activators [258].”
BackgroundInfluentialMitochondrial oxidative stress and dysfunction in myocardial remodelling
Tsutsui, H., Kinugawa, S., & Matsushima, S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn280 · Cited by 377
“Recently, small-molecule activators of SIRT1 have been shown to improve glucose homeostasis, increase insulin sensitivity in liver, skeletal muscle, and fat, and increase mitochondrial function in type 2 diabetic mice.(95) The interesting possibility that these interventions can prevent or ameliorate the onset and pro…”
BackgroundThe role of sirtuins in cardiac disease
Matsushima, S., & Sadoshima, J. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00053.2015 · Cited by 375
Chemistry and Biology of Resveratrol-Derived Natural Products
Keylor, M. H., Matsuura, B. S., & Stephenson, C. R. J. (2015) · Chemical Reviews · doi:10.1021/cr500689b · Cited by 366
Emerging roles of SIRT1 in fatty liver diseases
Ding, R.-B., Bao, J., & Deng, C.-X. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19370 · Cited by 359
“However, cautious evaluation on these newly developed SIRT1 agonists are still necessary to avoid any un-wanted side effects, especially for those later developed ones with 800-1000-fold more potency than resveratrol in activating SIRT1 [132].”
BackgroundLi, X. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms108 · Cited by 360
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice
Yao, H., Chung, S., Hwang, J.-W., Rajendrasozhan, S., Sundar, I. K., Dean, D. A., McBurney, M. W., Guarente, L., Gu, W., Rönty, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60132 · Cited by 358
Tanno, M., Kuno, A., Yano, T., Miura, T., Hisahara, S., Ishikawa, S., Shimamoto, K., & Horio, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.090266 · Cited by 358
Hormetic Dietary Phytochemicals
Son, T. G., Camandola, S., & Mattson, M. P. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8037-y · Cited by 356
Liang, F., Kume, S., & Koya, D. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.101 · Cited by 357
Walker, A. K., Yang, F., Jiang, K., Ji, J.-Y., Watts, J. L., Purushotham, A., Boss, O., Hirsch, M. L., Ribich, S., Smith, J. J., et al. (2010) · Genes & Development · doi:10.1101/gad.1901210 · Cited by 357
“2% DOSS) by oral gavage once a day for 2 or 4 wk as described (n = 5 per group) (Milne et al. 2007).”
BackgroundMethodInfluentialSelf-citationSirtuin activators and inhibitors
Villalba, J. M., & Alcaín, F. J. (2012) · BioFactors · doi:10.1002/biof.1032 · Cited by 352
“Administration of SRT1720 reduced fed glucose levels, partially normalizing elevated insulin levels, significantly reduced fasting blood glucose to near normal levels in mice on high-fat diet, strongly protecting mice from DIO and insulin resistance by enhancing oxidative metabolism in skeletal muscle, liver, and brow…”
Background
Metadata
- Authors
- Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J., & Westphal, C. H.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Westphal, Christoph H.
- ORCID
- Venue
- Nature
- Published
- 2007-11-29
- Volume
- 450
- Issue
- 7170
- Pages
- 712-716
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2753457
- OpenAlex
- W2116350182
- Cited by
- 1,707
- References
- 27
- Citations by year
- 2026: 38 · 2025: 43 · 2024: 55 · 2023: 55 · 2022: 68 · 2021: 100 · 2020: 80 · 2019: 75 · 2018: 82 · 2017: 69 · 2016: 92 · 2015: 89 · 2014: 110 · 2013: 119 · 2012: 126
- FWCI
- 55.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (P01AG027916, R01AG028730, R01AG019719)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- SIRT1, small molecule activators, type 2 diabetes, insulin resistance, caloric restriction mimetics, resveratrol, NAD+-dependent deacetylase, allosteric site, glucose homeostasis, mitochondrial function, obesity, aging, drug screening
- MeSH terms
- Resveratrol, Acetylation, Allosteric Site, Animals, Blood Glucose, Cell Line, Diabetes Mellitus, Type 2, Dietary Fats, Disease Models, Animal, Drosophila melanogaster, Heterocyclic Compounds, 4 or More Rings, Humans, Insulin, Male, Mitochondria, Rats, Zucker, Stilbenes, Rats, Sprague-Dawley, Catalytic Domain, Caloric Restriction, Sirtuins, Mice, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.